ALK and non-small cell lung carcinoma: A common site of metastases in non-small cell lung cancer (NSCLC) patients is in the brain where previous generation ALK inhibitors have limited effectiveness, and may be attributed to poor blood–brain barrier (BBB) penetration or active transport out of the brain by efflux pumps11, 12, 13.